Insmed Gains MHLW Approval In Non-Cystic Fibrosis Bronchiectasis Across Three Major Markets

Insmed's brensocatib (BRINSUPRI) has completed a three-jurisdiction approval arc, US, EU, and now Japan, establishing a multi-regional regulatory footprint for the first approved pharmacological treatment of non-cystic fibrosis bronchiectasis (NCFB). For regulatory affairs leads tracking parallel submission strategy for first-in-class therapies, the MHLW decision on 24 August 2026 closes a significant gap in global market access for this DPP1 inhibitor.

Japan's Ministry of Health, Labour and Welfare (MHLW) approved brensocatib 25-mg once-daily tablets for adults and pediatric patients aged 12 years and older, an age-range alignment that regulatory teams will note as consistent with the US and EU labeling scope. The approval is grounded in the Phase 3 ASPEN study, a 52-week placebo-controlled trial that demonstrated statistically significant reductions in pulmonary exacerbations, prolonged time to first exacerbation, increased proportion of exacerbation-free patients, and attenuated lung function decline as measured by post-bronchodilator FEV1 at week 52.

The safety profile reported in ASPEN is relevant to pharmacovigilance planning ahead of commercial launch. Treatment-emergent adverse events occurring in at least 5.0% of patients included COVID-19, nasopharyngitis, cough, and headache. Brensocatib was characterised as generally well tolerated, with no new safety signals identified relative to earlier-phase data, a point that will inform local risk management documentation required under Japanese post-marketing commitments.

From a regulatory strategy standpoint, Insmed's sequencing across the three ICH regions within a compressed window offers a working reference for teams managing concurrent submissions under ICH Q12-aligned lifecycle frameworks. The NCFB indication carried no approved comparator in any jurisdiction, which shaped the evidentiary standard and likely facilitated expedited review pathways in each market. Regulatory affairs teams benchmarking their own first-in-class dossiers against this timeline should examine how the ASPEN data package was structured to satisfy divergent agency requirements without requiring region-specific bridging studies.

Commercial readiness in Japan will now depend on MHLW pricing and reimbursement negotiations under the Chuikyo process, a step that typically precedes broad patient access by several months and carries its own submission and negotiation requirements distinct from the marketing approval itself.

The ASPEN 52-week FEV1 endpoint will serve as the primary benchmark against which post-marketing surveillance data in Japan will be assessed as real-world use accumulates.

Source: Insmed Incorporated via PR Newswire, 24 August 2026.